Welcome to our dedicated page for Organigram Global SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) provide structured insight into the company’s operations as a Canadian cannabis cultivator and manufacturer. As a foreign private issuer, Organigram files reports such as Form 40-F and Form 6-K with the U.S. Securities and Exchange Commission. Recent Form 6-K filings reference press releases, condensed consolidated interim unaudited financial statements, management’s discussion and analysis, and officer certifications for periods including the three and nine months ended June 30, 2025.
Through these filings, readers can access detailed information on Organigram’s financial performance, including net revenue, cost of sales, gross margin, adjusted gross margin, adjusted EBITDA and free cash flow, as well as balance sheet metrics such as cash, inventories, total assets, liabilities and shareholders’ equity. The filings also discuss non-IFRS financial measures, explaining how management uses these metrics to assess the company’s financial and operational results, and provide reconciliations to IFRS figures.
Organigram’s SEC submissions frequently include news releases that cover topics such as record quarterly and annual results, acquisitions like Motif Labs Ltd. and Collective Project Limited, international sales growth, and developments in hemp-derived THC and cannabinoid beverages. They also capture governance and leadership updates, including CEO succession plans and executive appointments, and describe the company’s regulatory context under the Cannabis Act and Cannabis Regulations in Canada.
On Stock Titan’s filings page for OGI, users can review these SEC documents as they are furnished to EDGAR and use AI-powered tools to help interpret complex sections. This includes quickly identifying key themes in earnings discussions, understanding changes in non-IFRS measures, and locating disclosures related to international expansion, extraction and processing facilities, and brand portfolio developments. The filings page also offers access to current reports on Form 6-K that incorporate significant press releases, providing a consolidated view of Organigram’s regulatory and disclosure history.
Organigram Global Inc. announced a C$65.2 million private placement from British American Tobacco’s subsidiary BAT to help fund its proposed acquisition of German cannabis company Sanity Group. BAT will subscribe for 14,027,074 shares at C$3.00 and exercise top-up rights for 9,897,356 shares at about C$2.34.
To keep BAT’s voting stake at or below 30% of Organigram’s common shares, much of the investment will be in non-voting Class A convertible preferred shares, initially convertible one-for-one and accreting at 7.5% per year until BAT and affiliates could hold up to 49% on a partially diluted basis. Based on 135,141,944 common shares outstanding, BAT is expected to receive 2,353,379 common shares and 21,571,051 preferred shares from the private placement.
Closing of both the acquisition and the financing depends on shareholder approval, Toronto Stock Exchange approval, and other regulatory clearances, including German foreign investment review. Disinterested shareholders must approve the related-party transaction under TSX rules and a "majority of the minority" vote is required under MI 61-101. The company plans to seek approvals at a March 30, 2026 meeting.
Organigram Global Inc. is expanding into Europe with a definitive deal to acquire Germany-based Sanity Group, a fast-growing medical and recreational cannabis company. Organigram will pay upfront consideration of €113.4 million, split between €80.0 million in cash and €33.4 million in Organigram shares, with potential additional earnout payments of up to €113.8 million based on Sanity’s performance.
The structure implies a total potential valuation of up to €250.0 million. Sanity’s net revenue grew from €9 million in 2023 to €60 million in 2025, with gross margins improving from 15% to 47%, and the business generated positive EBITDA in 2025. Organigram expects the deal to be financially accretive and to create a vertically integrated European hub, adding leadership positions in both Canada and the growing German medical cannabis market.
The cash portion will be funded by Organigram’s cash on hand, a new credit facility of up to $60 million with ATB Financial and lenders, and an expected C$65.2 million equity investment from British American Tobacco through a private placement and top-up rights. Closing is targeted for the second quarter of 2026, subject to shareholder approvals, TSX and German regulatory clearances, and completion of the financing arrangements.
Organigram Global Inc. reported strong growth for the quarter ended December 31, 2025, with net revenue rising to $63,538 from $42,730 a year earlier, driven by higher Canadian recreational and international sales and contributions from the Motif acquisition.
Gross margin before fair value adjustments improved to $23,517, a 37% margin, while adjusted gross margin reached $23,855 or 38%. Adjusted EBITDA increased to $5,265 from $1,410, and net income swung to a profit of $19,969 versus a prior-year loss.
The company ended the quarter with $62,966 in cash, restricted cash and short‑term investments and working capital of $162,494, but used $18,117 of free cash flow. Management guides for Fiscal 2026 net revenue above $300 million, higher adjusted gross margins than Fiscal 2025, higher adjusted EBITDA, and positive free cash flow with capital expenditures under $10,000.
Organigram held the #1 share of the Canadian recreational cannabis market as of December 2025 and is expanding internationally, supported by a $124.6 million follow‑on investment from BAT and the Jupiter Pool. However, a material weakness in internal control over financial reporting remains under remediation, and pending U.S. legislative changes could force a sale, wind‑down or restructuring of hemp‑derived THC activities by November 2026.
Organigram Global Inc. will report its first quarter fiscal 2026 results, for the period ended December 31, 2025, on Tuesday, February 10, 2026, before the market opens. The company will host a conference call that day at 8:00 a.m. Eastern Time for investors and analysts.
Participants must register online to receive personalized dial-in details and access codes, and a live webcast will also be available. A replay of the webcast will be posted on Organigram’s investor website within 24 hours and remain accessible for 90 days. The filing also reiterates the company’s cannabis-focused operations in Canada and includes standard forward-looking statement cautions.
GLOBAL INC. has set key dates for its upcoming annual and special meeting of security holders. The meeting will be held on March 30, 2026, and holders of common shares on record as of February 23, 2026 will be entitled to receive notice and vote.
The meeting will cover both regular annual business and special matters. Notice-and-access will not be used for either registered or beneficial shareholders, and the issuer will pay for delivery of proxy-related materials to objecting beneficial owners.
Organigram Global Inc., a Canadian cannabis company listed on the TSX and Nasdaq under the symbol “OGI”, filed its annual report on Form 40-F as a foreign private issuer using IFRS.
The report notes 134,461,029 common shares outstanding as of the fiscal year ended September 30, 2025 and incorporates audited consolidated financial statements, management’s discussion and analysis, and an annual information form by reference.
Management determined that the company’s disclosure controls and internal control over financial reporting were not effective as of September 30, 2025 because of material weaknesses, and the independent auditor issued an adverse opinion on the effectiveness of ICFR.
The filing outlines remediation steps completed in Q4 Fiscal 2025, including engaging internal control specialists, hiring a VP of Information Technology, dedicating resources to review third‑party service organization reports and remediating certain IT general controls, and describes the board’s independent audit, compensation, governance and investment committees, code of ethics and alignment with TSX and applicable Nasdaq corporate governance standards.